You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed/refractory central nervous system (CNS) lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Chemotherapy)

Not yet recruiting
  • CNS Lymphoma
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 22, 2023

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

CNS Lymphoma Trial in China (Selinexor, Rituximab, Methotrexate)

Not yet recruiting
  • Central Nervous System Lymphoma
  • Hefei, Anhui, China
  • +4 more
Jan 26, 2023

Lymphoma, Lymphoma Cns Trial in Boston (Fludarabine, Cyclophosphamide, Axicabtagene Ciloleucel)

Recruiting
  • Lymphoma
  • Lymphoma Cns
  • Boston, Massachusetts
  • +1 more
Jan 3, 2023

CNS Lymphoma Trial in Beijing (Zanubrutinib)

Recruiting
  • CNS Lymphoma
  • Beijing, Beijing, China
    Peking University People's Hospital
Aug 1, 2022

Primary CNS Lymphoma Trial in London (CD19CAR T-cells)

Recruiting
  • Primary CNS Lymphoma
  • CD19CAR T-cells
  • London, United Kingdom
    University College London Hospital
Jun 13, 2022

DLBCL Trial in Seoul (Tislelizumab, Pemetrexed)

Not yet recruiting
  • DLBCL
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 15, 2022

CNS Lymphoma Trial in Worldwide (GB5121)

Recruiting
  • CNS Lymphoma
  • Phoenix, Arizona
  • +5 more
Jul 26, 2022

CNS Lymphoma Trial in Chapel Hill, Winston-Salem (Acalabrutinib, Isavuconazole)

Recruiting
  • Central Nervous System Lymphoma
  • Chapel Hill, North Carolina
  • +1 more
Mar 24, 2022

Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Tumor in the CNS, Recurrent Diffuse Intrinsic Pontine Glioma Trial

Active, not recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • +10 more
  • FACT Complex-targeting Curaxin CBL0137
  • Birmingham, Alabama
  • +19 more
Jun 29, 2022

CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)

Recruiting
  • Central Nervous System B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

Recruiting
  • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
  • thiotepa combined with pomalidomide
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital.
Jun 27, 2023

CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)

Recruiting
  • CNS Lymphoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Aug 10, 2022

Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)

Active, not recruiting
  • Refractory Central Nervous System Lymphoma
  • +2 more
  • Hangzhou, Zhejiang, China
    Jianmin Zhang
Jul 3, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
    Beijing Tiantan Hospital, Capital Medical University
Jul 31, 2022

Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma Trial in Boston (Tisagenlecleucel)

Recruiting
  • Primary CNS Lymphoma
  • +2 more
  • Tisagenlecleucel
  • Boston, Massachusetts
    Massachusetts General Hospital
Jan 18, 2021

CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)

Recruiting
  • Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

CNS Lymphoma Trial in Essen ([90Y]Y-PentixaTher)

Recruiting
  • CNS Lymphoma
  • Essen, Germany
    University Hospital Essen
Nov 16, 2023

CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

Active, not recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • DISEASE
  • (no location specified)
May 4, 2023

CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)

Recruiting
  • Central Nervous System Lymphoma
  • Human CD19-CD22 Targeted T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

Non-hodgkin Lymphoma Trial (Methotrexate, Rituximab (where available), Ibrutinib)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • (no location specified)
Aug 11, 2023

Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

Suspended
  • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
  • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult Trial in Seattle (SC-CAR4BRAIN)

Not yet recruiting
  • Diffuse Intrinsic Pontine Glioma
  • +4 more
  • SC-CAR4BRAIN
  • Seattle, Washington
    Seattle Children's Hospital
Mar 3, 2023

CNS Lymphoma Trial in Zhengzhou (ICP-022, Pemetrexed)

Recruiting
  • Central Nervous System Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jan 28, 2022